{"id":708,"date":"2020-12-14T06:47:36","date_gmt":"2020-12-14T06:47:36","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=708"},"modified":"2020-12-14T06:47:57","modified_gmt":"2020-12-14T06:47:57","slug":"09-dec-2020-hydroxychloroquine-postexposure-therapy-with-hcq-did-not-prevent-sars-cov-2-infection","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/09-dec-2020-hydroxychloroquine-postexposure-therapy-with-hcq-did-not-prevent-sars-cov-2-infection\/","title":{"rendered":"(09 Dec 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 infection"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19<\/p>\n<p>https:\/\/doi.org\/10.1056\/NEJMoa2021801<\/p>\n<p class=\"\">An open-label, cluster-randomized trial (NCT04304053) involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, defined by symptoms compatible with Covid-19 or a positive PCR test regardless of symptoms. Adverse events were assessed for up to 28 days.&nbsp; The analysis included 2314 healthy contacts of 672 index case patients with Covid-19 who were identified between March 17 and April 28, 2020. A total of 1116 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care. Results were similar in the hydroxychloroquine and usual-care groups with respect to the incidence of PCR-confirmed, symptomatic Covid-19 (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]). In addition, hydroxychloroquine was not associated with a lower incidence of SARS-CoV-2 transmission than usual care (18.7% and 17.8%, respectively). The incidence of adverse events was higher in the hydroxychloroquine group than in the usual-care group (56.1% vs. 5.9%), but no treatment-related serious adverse events were reported. Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 https:\/\/doi.org\/10.1056\/NEJMoa2021801 An open-label, cluster-randomized trial (NCT04304053) involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/09-dec-2020-hydroxychloroquine-postexposure-therapy-with-hcq-did-not-prevent-sars-cov-2-infection\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(09 Dec 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 infection&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,9],"tags":[10],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/708"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=708"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/708\/revisions"}],"predecessor-version":[{"id":709,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/708\/revisions\/709"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}